People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Iambic Therapeutics, Inc. | — | Biotechnology | Series D+ | $240.9M | $697.8M | 2025 |
Michael Secora at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Secora on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jishnu Bhattacharjee | 1 | 9 |
| R. Jacob Vogelstein | 1 | 6 |
| Kurt Von Emster | 1 | 6 |
| Thomas Miller | 1 | 5 |
| Shalini Sharp | 1 | 4 |
| William Rastetter | 1 | 4 |
| Mary Tagliaferri | 1 | 3 |
| Evan Rachlin | 1 | 3 |
| Chao Zhang | 1 | 1 |
| Fred Manby | 1 | 1 |
| Neil Josephson | 1 | 1 |
| Pete Olson | 1 | 1 |
| Tabbert Teng | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.